Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Jagsonpal-Pharmaceuticals"

13 News Found

Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
News | February 09, 2023

Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%

Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
News | February 22, 2022

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma

The transaction as well as the open offer is expected to be completed by June this year.

Jagsonpal Pharma inks agreement with Suvinys Developers
News | February 19, 2022

Jagsonpal Pharma inks agreement with Suvinys Developers

Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.

Latest Stories

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging